SAHPRA Approves Groundbreaking HIV Prevention Injection
The South African Health Products Regulatory Authority (SAHPRA) has approved a new HIV prevention injection called Lenacapavir.
Developed by Gilead, the six-monthly injection is intended for adults and teenagers weighing at least 35 kilograms, and must be used in conjunction with safer sex practices, such as condom use.
SAHPRA collaborated with the European Medicines Agency to expedite access to essential treatments.
“The registration of Lenacapavir is a game-changer, given the high infection rate of HIV in South Africa. This product is the most effective HIV prevention measure thus far,”
said SAHPRA’s CEO, Dr Boitumelo Semete-Makokotlela.
Author's summary: SAHPRA approves Lenacapavir injection.
More News
- Amazon reportedly plans to cut around 30,000 corporate jobs | TechCrunch
- Frogs help Fred Hutch find the shape of small things
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- EU opens door to watered down climate law over 2040 emissions target impasse
- Flyers send Jett Luchanko back to juniors as development takes priority | NorthPennNow
- SJHN Daily: Celebrini Named NHL First Star of the Week